The London- and U.S.-listed pharmaceutical company said the warrants and units should be recorded as derivative liabilities and not equity instruments under both IFRS and U.S. GAAP accounting standards.
MarketWatch.com - Top Stories, MarketWatch
Mon, 02/21/2022 - 1:17am
The London- and U.S.-listed pharmaceutical company said the warrants and units should be recorded as derivative liabilities and not equity instruments under both IFRS and U.S. GAAP accounting standards.